News | February 14, 2026
Akums surges in Q3 FY26 with 15% revenue jump, bags key EU & UK nods
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The event will be attended by 35,000+ industry professionals
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Subscribe To Our Newsletter & Stay Updated
